The U.S. Food and Drug Administration has granted regenerative medicine advanced therapy (RMAT) designation to Fate's FT819 ...

The CAR T-cell therapy KYV-101 is safe, and showed preliminary signs of efficacy in patients with progressive forms of MS in ...

CAR T-Cell Therapy Market SizeThe global CAR T-cell therapy market was worth USD 11.11 billion in 2024 and is expected to ...

CAR-T 细胞疗法（Chimeric Antigen Receptor T-Cell Immunotherapy，嵌合抗原受体 T 细胞免疫疗法）是近年来新兴的一种细胞免疫治疗技术。它通过对患者自身的 T 细胞进行基因改造，使其表达嵌合抗原受体（CAR），从而能够特异性识别并杀伤肿瘤细胞。该疗法在血液系统恶性肿瘤的治疗中展现出了巨大潜力，为 MM ...

One concern with in vivo CAR-Ts is the potential insertional mutagenesis of the lentiviral DNA payload, causing secondary ...

The global CAR T-cell therapy market is on track for rapid growth, with projections indicating it will exceed USD 27.5 billion by 2033, up from USD 2.7 billion in 2025. This exponential rise in market ...

UAE's Burjeel Holdings has joined forces with US-based non-profit Caring Cross to locally manufacture CAR-T (Chimeric Antigen ...

CAR-T therapy costs about Rs 50 lakh in India including hospital fees, much less than the Rs 3-4 crore or more (before ...

At the GenScript Biotech Global Forum 2025, industry leaders celebrated CAR T cell therapy achievements while discussing ...

FDA has cleared an investigational new drug (IND) application to study switchable chimeric antigen receptor T cell (sCAR-T) therapy (CLBR001 + SWI019) in patients with autoimmune conditions. Patient ...

Taking a patient's immune cells and targeting their cancer with them, which is called CAR T cell therapy, is showing promise ...

Arovella Therapeutics at forefront of overcoming limitations of CAR-T cell therapy for cancer with its healthy donor-derived ...